Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1674
Title: Recent developments in medicinal chemistry of allosteric activators of human glucokinase for type 2 diabetes mellitus therapeutics
Authors: Grewal A S
Lather V
Charaya N
Sharma N
Singh S
Kairys V
Keywords: Allosteric
Antidiabetic
Diabetes mellitus
GK
GK activators
Glucokinase
Type 2 diabetes mellitus
Issue Date: 2020
Publisher: Bentham Science Publishers
Abstract: Background: Glucokinase (GK), a cytoplasmic enzyme catalyzes the metabolism of glucose to glu-cose-6-phosphate with the help of ATP and aids in the controlling of blood glucose levels within the normal range in humans. In pancreatic ?-cells, it plays a chief role by controlling the glucose-stimulated secretion of insulin and in liver hepatocyte cells, it controls the metabolism of carbohydrates. GK acts as a promising drug target for the pharmacological treatment of patients with type 2 diabetes mellitus (T2DM) as it plays an important role in the control of carbohydrate metabolism. Methods: Data used for this review was based on the search from several science databases as well as various patent databases. The main data search terms used were allosteric GK activators, diabetes mellitus, type 2 diabe-tes, glucokinase, glucokinase activators and human glucokinase. Results: This article discusses an overview of T2DM, the biology of GK, the role of GK in T2DM, recent updates in the development of small molecule GK activators reported in recent literature, mechanism of action of GK activators and their clinical status. Conclusion: GK activators are the novel class of pharmacological agents that enhance the catalytic activity of GK enzyme and display their antihyperglycemic effects. Broad diversity of chemical entities including benzamide analogues, carboxamides, acrylamides, benzimidazoles, quinazolines, thiazoles, pyrimidines, pyridines, orotic acid amides, amino acid derivatives, amino phosphates and urea derivatives have been synthesized in past two decades as potent allosteric activators of GK. Presently, the pharmaceutical companies and researchers are focus-ing on the design and development of liver-selective GK activators for preventing the possible adverse effects associated with GK activators for the long-term treatment of T2DM. � 2020 Bentham Science Publishers.
URI: 10.2174/1381612826666200414163148
http://hdl.handle.net/123456789/1674
Appears in Collections:Journals

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.